Merck & Co., Inc. vs United States Oil ETF — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while United States Oil ETF trades at $126.8. The key difference: Merck & Co., Inc. pays a 2.61% dividend while United States Oil ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| MRK | USO | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | — |
52-Week High | $131.84 | $152.96 |
52-Week Low | $77.60 | $66.17 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
USO trades at $127.30, up 1.1% today, with a bullish technical outlook supported by moving averages. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. Key support lies at $126, with resistance at $129.
The stock faces upside from supply constraints but risks include demand weakness and geopolitical uncertainty. Investors should weigh bullish technicals against fundamental headwinds in oil markets for balanced positioning.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →